#Abacavir Market

[abrreports-blog]

Abacavir Market Key Trends, Drivers, Growth Opportunities, and 2025 Industry Chain Structure Analysis

The research study Abacavir market 2020 launched by ABRReports.com provides the detailed analysis of current market status, investment plans, production and consumption, price trends, leading key companies, growth drivers and future prospect. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025

 Get the Sample Copy of Abacavir market report at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-abacavir-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report?form=request-report-sample

 The segmentation of Abacavir study as mentioned below:

By Market Players:

GSK, Aurobindo, Novnauki, Smilax, Hycultec, Atripla

 By Application

Hospital Pharmacy, Retail Pharmacy, Online PharmacyTablet, Oral Solution

 The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.

 The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

 Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-abacavir-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

 The key objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

 Purchase the research study @  https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-abacavir-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report/checkout?option=one

 Key pointers of the Table of Contents:

Chapter 1 Industry Overview

Chapter 2 Major Segmentation (Classification, Application and etc.) Analysis

Chapter 3 Production Market Analysis

Chapter 4 Sales Market Analysis

Chapter 5 Consumption Market Analysis

Chapter 6 Production, Sales and Consumption Market Comparison Analysis

Chapter 7 Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 8 Marketing Channel Analysis

Chapter 9 Industry Chain Analysis

Chapter 10 Global and Regional Market Forecast

Chapter 11 Major Manufacturers Analysis

Chapter 12 New Project Investment Feasibility Analysis

Chapter 13 Conclusions

Continued…

 About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company which offers market research reports to individuals, organizations and industries to enhance and strengthen the decision making process. With associate thoroughgoing list of market research Publishers we tend to cut across over all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trend, information on products, regional market and keen business insights to our clients.

 Contact Us:

Scott Harris

Sales Manager

Email ID: sales@abrreports.com

Phone No.: +1-561-448-7424

[bunnyroy]

Abacavir Industry Capacity, Production, Revenue, Price, Cost and Gross Margin Analysis 2018-2023

Abacavir Industry Capacity, Production, Revenue, Price, Cost and Gross Margin Analysis 2018-2023

MarketResearchNest.com presents “Global Abacavir Market Research Report 2018” new document to its studies database. The records spread across 100 with more than one tables and figures in it.   Description:- Abacavir Market Report 2017 offered by MarketResearchNest contains a market overview of the industry which talks about market size, product scope, market revenue, growth opportunities, sales…

[strategicbusinessreports-blog]

Global Abacavir Market Analysis, Size, Application Analysis, Regional Outlook, Competitive Strategies and Forecasts, 2017 To 2022

In this report, the Global Abacavir Market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Access Complete Report with Table of Content @ http://orianresearch.com/report/global-abacavir-market-research-report-2017

Global Abacavir Market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

Aurobindo

Novnauki

Smilax

Hycultec

Atripla

Request for free Sample Report @ http://orianresearch.com/request-sample/Global-Abacavir-Market-Research-Report-2017

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Tablet

Oral Solution

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Abacavir for each application, including

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), Market Share and Growth Rate of Abacavir in these regions, from 2012 to 2022 (forecast), covering

North America

Europe

China

Japan

Southeast Asia

India

If you have any special requirements, please let us know and we will offer you the report as you want.

http://orianresearch.com/enquiry-before-buying/Global-Abacavir-Market-Research-Report-2017  

Table of Contents included in Global Abacavir Market Report

Global Abacavir Market Research Report 2017 1 Abacavir Market Overview

2 Global Abacavir Market Competition by Manufacturers

3 Global Abacavir Capacity, Production, Revenue (Value) by Region (2012-2017)

4 Global Abacavir Supply (Production), Consumption, Export, Import by Region (2012-2017)

5 Global Abacavir Production, Revenue (Value), Price Trend by Type

6 Global Abacavir Market Analysis by Application

7 Global Abacavir Manufacturers Profiles/Analysis

See Continue Complete TOC for which is Companies covered in Global Abacavir Market @ http://orianresearch.com/report/global-abacavir-market-research-report-2017

About Us

Orian Research is one of the most comprehensive collection of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the world's most complete and current database of expert insights on global industries, companies, and products.

Contact Us

Ruwin Mendez

Vice President – Global Sales

Email: info@orianresearch.com

Web: http://orianresearch.com/

+1 (832) 380-8827

+44 0161-818-8027

[healthcare-market]

Pharmacogenomics Market Insights Shared in Detailed Report

Pharmacogenomics is the study of inherited variations in human genes that affect an individual’s reaction to a particular drug. It co-integrates genetic science with pharmaceutical science. Hence, it is the science of individualizing a drug based on an individual’s genetic makeup. Pharmacogenomicsis also linked to personalized medicine, as environmental conditions, genetic variations, and changing lifestyle greatly influence the type and severity of diseases as well as therapeutic responses that vary from person to person. In pharmacogenomics, various genetic tests are performed to determine or assist in targeted drug therapies as well as treatment procedures to be adopted to minimize side effects and improve results. The genetic tests performed in pharmacogenomics also help to determine an individual’s susceptibility to certain diseases. Presently, pharmacogenomics is being considered to bring a new change in medicine and health care as it promises to offer better, safer, and affordable health care.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3615

Major factors driving the market are increasing prevalence of several infectious and non-infectious diseases, rising usage in drug discovery processes, increasing demand for personalized drugs, and growing awareness about benefits associated with pharmacogenomics. Diseases require effective treatment therapeutics, which must be more reliable and safe at the same time. Pharmacogenomics can help achieve both. Hence, increasing awareness about its benefits is likely to drive demand across regions. Application of pharmacogenomics would greatly help physicians in the treatment of a particular segment of population by studying their responses to specific drugs. Moreover, the knowledge of effectiveness of a drug in a patient would make a drug more reliable, and limit the number of drugs to be withdrawn from the market due to different adverse reactions in few patients to whom they were administered. Several pharmacogenomics tests have been developed and some are under development. This represents tangible deliverables of the numerous genomic studies to correlate genetic variation with variable drug response. Certain drugs such as warfarin, thiopurines, clopidogrel, irinotecan, abacavir, carbamazepine, and phenytoin are used for pharmacogenomics tests. These tests are performed for diseases such as excessive clotting disorder, autoimmune/childhood leukemia, cardiovascular, cancer, HIV, epilepsy, and psychiatric and related diseases. Pharmacogenomics is also facing challenges such as predicting the association between a genetic marker and a phenotypic drug response, where other variables are also playing their role in drug response. However, recent technological advancements will overcome the challenges in future.

Request for Analysis of COVID19 Impact on Pharmacogenomic (PGx) Testing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=3615

North America holds the leading position in the pharmacogenomics market, followed by Europe. Growth of the market in these regions is attributed to increasing usage of pharmacogenomics in the development of more potent as well as personalized medicines, which have significant demand in these regions. High awareness among physicians and drug developers about the benefits, such as increased reliability and reduced side effects, is likely to boost the growth of the market in these regions. Asia Pacific is the most lucrative market. Key factor responsible for the rapid growth of this market in the region is increasing demand for better, safer, and cost effective therapeutics for several infectious and non-infectious diseases prevalent in this region. Other factors include increasing health care awareness, improving health care investments, rising number of R&D centers, and demand for personalized drugs.

Pre-Book Pharmacogenomic (PGx) Testing Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=3615&ltype=S

Major players operating in the pharmacogenomics market are Affymetrix, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Bayer AG, Merck & Co., Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Myriad Genetics, Inc., and Pathway Genomics Corporation.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.co.uk/news-releases/sizeable-numbers-to-endorse-benefits-and-efficacy-of-umbrella-of-hormone-replacement-therapies-underscores-growth-in-testosterone-replacement-therapy-market-valuation-projected-to-touch-us-2-2-bn-by-2027-says-tmr-819153496.html

https://www.prnewswire.com/news-releases/global-optical-lens-edger-market-to-thrive-on-growing-popularity-of-digital-camera-market-projected-to-clock-impressive-6-5-cagr-from-2018--2026--tmr-301283241.html

https://www.prnewswire.com/news-releases/manufacturers-in-injection-pen-market-aimed-at-improving-diabetes-care-to-propel-constant-design-advances-by-2030-global-valuation-to-climb-to-us-6-bn-tmr-301287473.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com

[renubresearchanalysis]

United States Generic Drugs Market Share, Size , Forecast By 2026

Generics are an off-patented drug that is pharmaceutical equivalents to branded medicines in term of administrative dosage, quality, effect, intended use and side effects. In the United States, generic drug production has increased because it is cheaper than any branded medicine. From the last 3 decades, U.S generic drug market has transformed from less than 20% of generic drug prescription to 80% of dispensing generic medicine prescriptions. As per the Renub Research report, United States Generic Drugs Market will be US$ 239.5 Billion by 2026.

Generic medicines help maintain the country's healthcare system, from curing patients to saving money. Currently, the price of off-label drugs is 70% to 80% lower than branded medicines. In the United States, the decline in medicine price works as the biggest catalyst for the generic drug market growth. These generic medicines prices sometimes declined to 85% less than patented drugs; this happens when various generic drug companies target a single patented drug. Our research findings suggest that the United States Off-Label Drugs market will grow with a CAGR of 5.69% in future from 2020 to 2026.

Follow the link for the full report with detailed TOC and list of figures and tables: https://www.renub.com/united-states-generic-drugs-market-p.php

The United States government awareness for the use of generic drugs reduces overall health expenditure in the country. The FDA's Office of Generic Drugs (OGD) within the Center for Drug Evaluation in Research ensures access to safe, high quality and affordable drugs to Americans. The U.S government made a law regarding the generic drug, allowing a new player to enter the market. Besides factors like the rising number of patients for diabetes, Alzheimer, cardiac diseases, an increasing number of drug patent expirations and government initiatives expected to drive the generic drugs industry. As per this research study, the United States Off-patent Drugs Market was US$ 171.8 Billion in the year 2020.

Generic Drug Companies Deals

On July 6, 2020, Endo announced that it had received FDA approval of Qwo® (collagenase clostridium histolyticum-aaes). Another company, named Lupin Limited manufactures generic drug Abacavir& Lamivudine, whose combination is being used together with other medications to treat human immunodeficiency virus (HIV) infection. We have covered companies’ initiatives that sell various generic drugs in the United States. Companies covered in the report are Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited, Dr Reddy's and Sun pharma.

Renub Research report title “United States Generic Drugs Market’’ By Segment (Generic, Branded), Therapy Area (CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti – infective, Oncology and Others), Pharmaceutical (Branded Pharmaceutical, Generics Pharmaceutical), Company (Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited , Dr Reddy's and Sun pharma)” provides an all-encompassing analysis on the US Generic Drug Industry.

Request a Free Sample Copy of the Report:  https://www.renub.com/request-sample-page.php?gturl=united-states-generic-drugs-market-p.php

Segment: Market breakup from 2 viewpoints

• Generic • Branded

Therapy Area: Market breakup from 8 viewpoints

1. CNS 2. Cardiovascular 3. Dermatology 4. Genitourinary/Hormonal 5. Respiratory 6. Anti – infective 7. Oncology 8. Others

Pharmaceutical: Market breakup from 2 viewpoints

• Branded Pharmaceutical • Generics Pharmaceutical

All the Company Analysis have covered 3 Viewpoints

• Overview • Recent Developments • Revenue Analysis

Company Analysis

1. Teva Pharmaceutical Industries Ltd 2. Mylan N.V 3. Sandoz Inc. 4. Endo Pharmaceuticals 5. Lupin Limited 6. Dr Reddy's 7. Sun pharma

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building and Construction, & Agriculture. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Our core team is comprised of experienced people holding graduate, postgraduate and PhD degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research helps to make business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them with findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today's ultra-competitive markets.

Contact Us: Renub Research Phone No: +1 678–302–0700 (USA) | +91–120–421–9822 (IND) Email: info@renub.com Web: https://www.renub.com Follow on Linkedin: https://www.linkedin.com/company/renub-research

[bigyack-com]

New Strawberry-Flavored H.I.V. Drugs for Babies Are Offered at $1 a Day

About 80,000 babies and toddlers die of AIDS each year, mostly in Africa, in part because their medicines come in hard pills or bitter syrups that are very difficult for small children to swallow or keep down.But on Friday, the Indian generic drug manufacturer Cipla announced a new, more palatable pediatric formulation. The new drug, called Quadrimune, comes in strawberry-flavored granules the size of grains of sugar that can be mixed with milk or sprinkled on baby cereal. Experts said it could save the lives of thousands of children each year.“This is excellent news for all children living with H.I.V.,” said Winnie Byanyima, the new executive director of UNAIDS, the United Nations agency in charge of the fight against the disease. “We have been eagerly waiting for child-friendly medicines that are easy to use and good to taste.”Cipla revolutionized the provision of AIDS drugs for adults almost two decades ago, pricing them at $1 a day. The new pediatric formulation will likewise be priced at $1 a day. The announcement by Cipla and the Drugs for Neglected Diseases Initiative, an offshoot of Doctors Without Borders that supported the development of the drug, was timed to coincide with World AIDS Day, which is Sunday.Despite big advances in the prevention of mother-child transmission of H.I.V., about 160,000 children are still born infected each year, according to UNAIDS, mostly in the poorest towns and villages of Africa. Almost half of them die before the age of 2, usually because they have no access to drugs or cannot tolerate them.Quadrimune is still under review by the Food and Drug Administration, and F.D.A. approval almost inevitably leads to rapid certification by the World Health Organization. The company hopes to get a decision by May. Trials in healthy adults showed that the new formulation gets the drugs into the blood; the four drugs in it were approved in the 1990s and are used in many combinations.A clinical trial in H.I.V.-infected infants, run by Epicentre, the research arm of Doctors Without Borders, is now underway in Uganda to prove to African health ministries that children accept the new formulation. Most of the research costs have been paid by UNITAID, a Geneva-based organization set up by​ France, Norway, Brazil and some other countries ​which imposed special taxes on airline flights that are dedicated to ​bettering​ global health. Currently, the most common pediatric drug combination includes a syrup that is 40 percent alcohol, has a bitter metallic taste that lingers for hours and must be transported in cold trucks and then kept in a refrigerator — something that many poor rural families do not own.“Some families try to bury it in wet sand or dirt to keep it cool,” said Dr. Bernard Pécoul, executive director of the neglected diseases initiative. “And the children are vomiting it on a regular basis.” Moreover, each drug must be squirted into a child’s mouth with a separate syringe, so a mother must have up to four syringes on hand and clean them for each subsequent use. Children generally have to take the medicines twice a day for the first four years of life. When liquid versions are unavailable, some pills cannot be crushed and mixed in juice; they must be swallowed whole. In contrast, Quadrimune contains four H.I.V. drugs: ritonavir, lopinavir, abacavir and lamivudine. The granules are coated first in a polymer that doesn’t melt until it reaches the stomach, and then with sweet, fruity flavoring. Dr. Kogie Naidoo, who heads treatment research at Caprisa, an AIDS treatment and research group based in Durban, South Africa, who was not involved in Quadrimune’s development, said the new formulation could solve many problems she and her colleagues encounter while treating children. Cipla, founded in 1935, was the first generic drug company to offer H.I.V. drugs in Africa. In 2001, its chairman, Yusuf K. Hamied, upended the global pharmaceutical industry by offering to supply a three-drug cocktail to Doctors Without Borders for $1 a day. At the time, multinational drug companies were charging up to $15,000 for their regimens and refusing to lower prices except in secret negotiations with a few countries and were working to block generic competitors from the market. An estimated 25 million Africans were then infected and thousands were dying every day. (The industry was also suing South Africa’s president, Nelson Mandela, over a law he had signed authorizing the government to cancel drug patents and award them to generic makers.)In 2001, Dr. Hamied said he was losing money at the $350 a year price; his break-even point was $600, he said, and he offered it to other buyers for that.But he said he acceded to requests from AIDS activists for the $1 a day price to deliver a shock to his Western competitors and because such a nice round figure was likely to make headlines (a gambit he is clearly repeating now).In the decades since, increased generic competition has driven the price of triple therapy in poor countries to below $100 a year.“Over the past 20 years, Cipla has pioneered fixed-dose combinations for children and I do believe our Quadrimune could be a winner,” Dr. Hamied said in an interview this week. Because all four drugs in the formulation are older and no longer patented, Cipla might eventually offer it in wealthy countries too, he said. But that market is quite small because most pregnant women in the West are tested for H.I.V. and immediately put on antiretroviral drugs, which reduces to near zero the chances that they will infect their babies in the womb, during birth or through breastfeeding.The $1 a day price is for Quadrimune doses appropriate for children of between 20 and 30 pounds, he noted, so the cost for newborns would be even lower.Paradoxically, treating infants with H.I.V. has actually become harder in recent years than it was two decades ago.In the early 2000s, Cipla produced Triomune Baby and Triomune Junior, two pediatric formulations of the world’s first adult three-in-one pill, introduced in 2001. But they contained nevirapine, a drug that in those days was often given to pregnant women to prevent mother-child transmission. As a result, many babies were born with nevirapine-resistant forms of the virus, and the efficacy of pediatric Triomune fell by about half, Dr. Pécoul said.Some nevirapine substitutes that work in adults do not work well in children, and the combination that does work has the bitter taste.Nowadays, many pediatric H.I.V. specialists are frustrated that they cannot prescribe some of the newest drugs, such as tenofovir and dolutegravir, because there is little or no data on how safe they are in small children. The major drugmakers have little incentive to test their products in children because there are so few customers who can pay high prices.If a child’s virus develops resistance to any regimen, a new one must be tried, so more research is needed, said Dr. Naidoo, the AIDS researcher in Durban.But by any measure, she said, Cipla’s new, gentler formulation for children is a major advance: “This is indeed great news for treating pediatric H.I.V.” Source link Read the full article

[pharmaphorumuk]

Shingrix and Trelegy shield GSK from Advair fallout

GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs have helped offset the impact of generics on its Advair blockbuster in the US.

The star of the show in the third quarter was shingles vaccine Shingrix, sales of which rose by 87% to reach £535 million, well ahead of analyst expectations, on the back of strong uptake in the US, Canada and Germany.

New respiratory drugs Nucala (mepolizumab) for severe asthma and Advair follow-up Trelegy (fluticasone furoate, umeclidinium, and vilanterol) made a solid supporting cast in the three-month period. Nucala rose 40% to £203 million, while Trelegy for chronic obstructive pulmonary disease (COPD) more than doubled to £139 million.

The growth products helped GSK to a 16% increase in turnover to £9.39 billion, despite Advair continuing its steady decline with a fall of a third to £418 million, with a two-thirds decline in the US market.

The turnover increase was improved by the consolidation of Pfizer’s consumer health business into a new joint venture, but even without that boost was still up 11%.

GSK chief executive Emma Walmsley has said since taking the helm that GSK needs its new products to fire on all cylinders while it revamps a new product portfolio that has been viewed as a lacklustre, and the first objective seems to be on track, with the company raising its earnings guidance for the year from a loss to flat.

On the second, Walmsley said GSK is gearing up for three new filings in oncology before the end of the year.

The includes BCMA-targeting antibody-drug conjugate belantamab mafodotin for fourth-line multiple myeloma treatment, as well as recently-acquired PARP inhibitor Zejula (niraparib) as a first-line maintenance therapy for ovarian cancer and PD-1 inhibitor dostarlimab in second-line endometrial cancer.

Trelegy has also been filed for approval in asthma, and Nucala picked up its first approval – in Europe – in a new self-administered formulation that should help cement its position as the lead biologic for severe asthma in the market, said Walmsley.

It wasn’t all positive news, however. GSK’s HIV franchise – sold via its ViiV joint venture – has been among its best performers for some time, but overall revenues for the business were flat in the third quarter due to increased competition, mainly from arch-rival Gilead Sciences.

GSK has been pushing its two-drug combinations for HIV such as Juluca (dolutegravir/rilpivirine) and new launch Dovato (dolutegravir/lamivudine), but chief financial officer Iain Mackay said the company “has anticipated it will take several quarters for them to become a significant contributor to growth”.

Together the two new drugs made £119 million in the third quarter, which GSK said offset declines in three-drug combination Triumeq (abacavir/dolutegravir/lamivudine), which has been hit by competition, notably from Gilead’s fast-growing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

There was also the usual update on R&D casualties, which this time included  RIP1k inhibitor GSK3145095 for pancreatic cancer, and PI3Kd inhibitor GSK2292767 for respiratory diseases.

The post Shingrix and Trelegy shield GSK from Advair fallout appeared first on .

from https://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/

[chetanare]

Abacavir Market Overview 2020-2026

Abacavir Market Overview 2020-2026

The recent research report titled “Global (Covid-19 Impact) Abacavir Sales Market (Sales,Revenue and competitors Analysis of Major Market) from 2014-2026” has been added in the kandjmarketresearch.com database. This market report is a valuable source of insightful data for business strategists. It offers the industry overview with growth analysis and historical & futuristic cost, revenue, demand,…

[marketreportszone-blog]

Abacavir Market Forecast Analysis by Regions and Segments To 2024

Geographically, global Abacavir Market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer the top players including

·       GSK

·       Aurobindo

·       Novnauki

·       Smilax

·       Hycultec

·       Atripla

 On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split into

·       Tablet

·       Oral Solution

 For the end users applications, this report focuses on the status and outlook for major applications end users, consumption (sales), market share and growth rate of Abacavir for each application, including

·       Hospital Pharmacy

·       Retail Pharmacy

·       Online Pharmacy

 Request A Free Sample copy of This Report @

https://www.marketreportszone.com/sample-report/2909-global-abacavir-market

 Production, consumption, revenue, market share and growth rate are the key targets for Abacavir from 2013 to 2024 (forecast) in these regions

·       China

·       USA

·       Europe

·       Japan

·       Korea

·       India

·       Southeast Asia

·       South America

 If you have any special requirements, please let us know and we will offer you the report as you want.

 Browse Detailed Abacavir Market Research Report @

https://www.marketreportszone.com/industry-report/2909-global-abacavir-market

 Table of Contents

 1 Report Overview

2 Market Analysis by Types

3 Product Application Market

4 Manufacturers Profiles Analysis

5 Market Performance for Manufacturers

6 Global Abacavir Market Performance (Production Point)

7 Development Trend for Regions (Production Point)

8 Global Abacavir Market Performance (Consumption Point)

9 Development Trend for Regions (Sales Point)

10 Upstream Source, Technology and Cost

11 Channel Analysis

12 Consumer Analysis

13 Market Forecast 2019-2024

14 Conclusion

  Explore More Healthcare and Pharmaceutical Related Market Reports @

https://www.marketreportszone.com/category/healthcare-and-pharmaceutical

[assetsstock-blog]

Global Abacavir Market Outlook 2018-2023 Industry Growth and Competitive Landscape Trends, Segmentation, Industry

Global Abacavir Market Outlook 2018-2023 Industry Growth and Competitive Landscape Trends, Segmentation, Industry

New Research Report On “Global Abacavir Market 2018”Insights, Forecast To 2023. This report presents the comprehensive Abacavir market measurement (value, demand, supply, production also consumption), splits the information further by manufacturers, regions, types and applications from 2018 to 2023. This report has established the market scenario in an orderly way, emphasizing the industrial…

[pharmaceuticalsmarketreports]

Abacavir (ABC) Market Share,Growth And Forecast Report 2017 By Radiant Insights,Inc

The Abacavir (ABC) Market 2017 Report offers detailed analysis of the Abacavir (ABC) market over the last five years, and provides extensive market forecasts by region/country and sub sector. It covers the key technological and market trends in the Abacavir (ABC) market. It further lays out an analysis of the factors influencing the supply/demand for Abacavir (ABC), and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

Request A Sample Copy of This Report at: https://www.radiantinsights.com/research/global-and-chinese-abacavir-abc-market-outlook-2017-2022/request-sample

In particular, it provides an in-depth analysis of the following:

Market overview: detailed analysis of the whole value chain (upstream & downstream), insights into technological developments, and an extensive analysis of costs analysis from the aspects of raw materials, labor costs and etc.

Market size and driving factors: comprehensive analysis of the global Abacavir (ABC) market during the 2012-2022 period, including market volume & value, growth and development trends, demand drivers and stimulators for Abacavir (ABC). It also provides an insight on the spending pattern and application pattern in different regions around the world.

Competitive landscape analysis: exhaustive analysis of top players on the market performances (sales and market position), strengths & weaknesses, opportunities and threats. It also provides the current consolidation trends in the industry and the challenges faced by industry participants.

Browse Full Research Report with TOC on https://www.radiantinsights.com/research/global-and-chinese-abacavir-abc-market-outlook-2017-2022

Worldwide supply/demand pattern: analysis of the key markets in each region (North America, Europe, Asia-Pacific, ChinaMiddle East & Africa), providing an analysis of the top segments of Abacavir (ABC) expected to be in demand.

Tends forecast: analysis of regional demand and growth trends, all the numbers, both - sales & volume, at each level of the detail are estimated till 2022, to give a glimpse of the potential market size in terms of value in this market.

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact:

Michelle Thoras

201 Spear Street 1100,

Suite 3036, San Francisco,

CA 94105, United States

Tel: 1-415-349-0054

Toll Free: 1-888-928-9744

Mail: sales@radiantinsights.com

[healthcarepharma-blog]

Global Abacavir Sales Market Strategies and Forecasts, 2017 to 2022

Festive Month Offer -

20% discount on purchase of reports from 1st October to 31st October.

https://www.researchtrades.com/discount/1275037

For more offers post 31st October, kindly contact us. * Terms & Conditions apply!!

Contact No. : +16269994607 (US), /+91 7507349866 (IND)

Email: sales@researchtrades.com

 Report Overview:

The “Global Abacavir Sales Market Research Report” is a professional and in-depth study on the current state of the Abacavir Sales Market. The study offers an insight into current and future market trends, key drivers and restraints, market strategies of key market players along with detailed segmentation and forecast. The study offers industry overview by covering basic aspects such as product definition and classification, market size and share of segments and sub-segments. This report offers market insights into the changing dynamics by analysis the elements of industry chain structure, key marketing channels and the innovative strategies adopted by key market players to gain a competitive advantage in the market.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Abacavir for these regions, from 2012 to 2022 (forecast), covering

United States

China

Europe

Japan

Southeast Asia

India

 Get Exclusive sample copy @ https://www.researchtrades.com/request-sample/1275037

 Global Abacavir market competition by top manufacturers/players, with Abacavir sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

GSK

Aurobindo

Novnauki

Smilax

Hycultec

Atripla

...

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Tablet

Oral Solution

 On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Abacavir for each application, including

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

 Table of Contents

1 Abacavir Market Overview

1.1 Product Overview and Scope of Abacavir

1.2 Classification of Abacavir by Product Category

1.2.1 Global Abacavir Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 Global Abacavir Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 Tablet

1.2.4 Oral Solution

1.3 Global Abacavir Market by Application/End Users

1.3.1 Global Abacavir Sales (Volume) and Market Share Comparison by Application (2012-2022)

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

 2 Global Abacavir Competition by Players/Suppliers, Type and Application

2.1 Global Abacavir Market Competition by Players/Suppliers

2.1.1 Global Abacavir Sales and Market Share of Key Players/Suppliers (2012-2017)

2.1.2 Global Abacavir Revenue and Share by Players/Suppliers (2012-2017)

2.2 Global Abacavir (Volume and Value) by Type

2.2.1 Global Abacavir Sales and Market Share by Type (2012-2017)

2.2.2 Global Abacavir Revenue and Market Share by Type (2012-2017)

2.3 Global Abacavir (Volume and Value) by Region

2.3.1 Global Abacavir Sales and Market Share by Region (2012-2017)

….

Browse This Report @ https://www.researchtrades.com/report/global-abacavir-sales-market-report-2017/1275037

Who we are

Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

[pharmaphorumuk]

ViiV hopes for blockbuster with HIV drug combo approval

The FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for treatment-naïve patients, making it the only company to have such a drug on the market.

The approval follows a priority review by the FDA and  is supported by the global GEMINI 1 and 2 studies, which showed that the two drug combination is as effective at suppressing the disease as a commonly-used three drug combination, but with fewer side effects.

This is important for patients who have to keep taking the drugs to ensure the virus is kept at bay and does not progress to cause AIDS.

Christopher Pace, senior director of infectious diseases and respiratory at GlobalData, said that he expects the drug to achieve blockbuster status in the coming years.

He noted that the approval allows the GSK-led joint venture to more effectively compete against its main rival Gilead, whose Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [TAF]) has dominated the market with sales of over $1.1 billion globally since its approval in February 2018.

“Based on the solid data from the GEMINI 1 and 2 studies, I expect Dovato will quickly gain traction as a first-line option for patients newly diagnosed with HIV,” he said, “particularly those who would otherwise be precluded from receiving Triumeq (abacavir/dolutegravir/lamivudine) due to abacavir hypersensitivity.

“Juluca (dolutegravir/rilpivirine), ViiV’s other marketed 2-drug regimen, has struggled out of the gate against Biktarvy, largely due to the fact that it is only approved for HIV patients who have achieved viral suppression with another antiretroviral therapy. While recently reported data from the SWORD 1 and 2 studies have strengthened Juluca’s position as an attractive long-term maintenance therapy, its inability to access treatment-naïve patients remains a key limitation in a market where switching patients from one regimen to another can prove challenging.”

He added that ViiV’s pricing strategy with Dovato will be worth closely monitoring, as inexpensive generic versions of lamivudine are widely available.

“Historically, payers have been willing to reimburse branded 3- and 4-drug STRs to ensure improved compliance over less expensive, multi-tablet regimens, but it remains to be seen whether or not the same will be true for 2-drug STRs such as Dovato.

“If the cost of prescribing Tivicay (dolutegravir) plus generic lamivudine is substantially lower than the cost of Dovato, it’s possible clinicians and payers could consider this approach.”

Dovato is also currently under review by the EMA.

ViiV is also working with Janssen to develop a once-monthly injectable HIV combo regimen, which recently reported positive phase 3 trial results.

The post ViiV hopes for blockbuster with HIV drug combo approval appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/viiv-hopes-blockbuster-hiv-drug-combo-approval/